Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2016 07:00 ET | Source: ArQule, Inc.

ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer

75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
June 23, 2016 07:00 ET | Source: ArQule, Inc.

ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer

BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...
December 15, 2015 07:30 ET | Source: ArQule, Inc.

ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 087

Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...
November 09, 2015 07:55 ET | Source: ArQule, Inc.

UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference

Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
November 09, 2015 07:30 ET | Source: ArQule, Inc.

ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference

Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
October 27, 2015 07:30 ET | Source: ArQule, Inc.

ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference

Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...